| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/20/2005 | US20050013815 Prevention and treatment of amyloidogenic disease |
| 01/20/2005 | US20050013795 A proteinaceous part having TNF activity and a high molecular polyethylene part bound artificially to the N-terminus of the proteinaceous part, with higher stability; antitumor agents |
| 01/20/2005 | US20050013792 Dispersion containing ion exchange matrix drug complex; shelf life |
| 01/20/2005 | US20050013791 Cytokine-inducing material and cytokine-inducing instrument |
| 01/20/2005 | US20050013775 Stability; intermetallic covalently linked to biological vector molecule; delivering radiolabel in tumor treatment or diagnosis |
| 01/20/2005 | DE20221087U1 Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen Transdermal therapeutic system with fentanyl and related substances |
| 01/20/2005 | DE10330243A1 Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis Use of products derived from extremophilic bacteria osmolytes for the production of drugs for external treatment of atopic dermatitis |
| 01/20/2005 | DE10330026A1 Using sweetener acid for stabilization of foods, cosmetics, consumer goods and pharmaceuticals, provides low pH with less perceived acidity, compared with usual food acids |
| 01/20/2005 | CA2531629A1 Medicinal composition containing nf-.kappa.b decoy for treating and preventing respiratory diseases and method of using the same |
| 01/20/2005 | CA2531419A1 Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment |
| 01/20/2005 | CA2531283A1 Specific human antibodies |
| 01/20/2005 | CA2531118A1 Multivalent carriers of bi-specific antibodies |
| 01/20/2005 | CA2530531A1 Formulations for coated microprojections containing non-volatile counterions |
| 01/20/2005 | CA2529606A1 Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
| 01/19/2005 | EP1498150A1 Delivery of solid drug compositions |
| 01/19/2005 | EP1498144A1 Extracellular vesicles from non-pathogenic amoebae useful as vehicle for transferring a molecule of interest to an eukaryotic cell |
| 01/19/2005 | EP1498143A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 01/19/2005 | EP1498142A1 Polyfunctional biocompatible hydrogel and method for the production thereof |
| 01/19/2005 | EP1498141A1 Stable non-dihydrate azithromycin oral suspensions |
| 01/19/2005 | EP1498135A1 Dental viscous pharmaceutical containing basic fibroblast growth factor |
| 01/19/2005 | EP1498123A1 Emulsifying systems containing azetidine derivatives |
| 01/19/2005 | EP1498122A1 Semi-solid systems containing azetidine derivatives |
| 01/19/2005 | EP1498119A1 Use of conjugated linoleic acid for treating colds |
| 01/19/2005 | EP1498118A1 Patch and process for producing the same |
| 01/19/2005 | EP1498115A1 Preparation of particles for inhalation |
| 01/19/2005 | EP1497466A2 Binary or polynary targeting and uses thereof |
| 01/19/2005 | EP1497454A2 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| 01/19/2005 | EP1497445A2 Antibodies that specifically bind to gmad |
| 01/19/2005 | EP1497442A2 Biologic modulations with nanoparticles |
| 01/19/2005 | EP1497436A1 Compositions for delivering enzymes involved in amino acid metabolism using recombinant adeno-associated virus virons (raav virons), and method and use for treating amino acid metabolic disorders using such raav virons |
| 01/19/2005 | EP1497411A1 Embryo modification and implantation |
| 01/19/2005 | EP1497314A2 Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| 01/19/2005 | EP1497297A1 Polymorph of ascomycin derivative |
| 01/19/2005 | EP1497289A1 Medicaments containing betamimetic drugs and a novel anticholinesterase drug |
| 01/19/2005 | EP1496979A2 Protamine-adenoviral vector complexes and methods of use |
| 01/19/2005 | EP1496951A1 Wound dressings comprising hydrated hydrogels and enzymes |
| 01/19/2005 | EP1496942A1 Microparticles comprising carbohydrate beads covalently linked with allergen |
| 01/19/2005 | EP1496941A1 Glycodendrimers having biological activity |
| 01/19/2005 | EP1496934A2 Adjuvant enhanced immunotherapy |
| 01/19/2005 | EP1496933A2 Use of interleukin-19 to treat ovarian cancer |
| 01/19/2005 | EP1496932A2 Anti-hiv composition, production method thereof and medicament |
| 01/19/2005 | EP1496927A2 Targeted immunogens |
| 01/19/2005 | EP1496926A1 Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| 01/19/2005 | EP1496925A2 Use of interleukin-24 to treat ovarian cancer |
| 01/19/2005 | EP1496919A2 Immobilisation and stabilisation of virus |
| 01/19/2005 | EP1496916A2 Metastasis modulating activity of highly sulfated oligosaccharides |
| 01/19/2005 | EP1496912A1 Combination of brimonidine and timolol for topical ophthalmic use |
| 01/19/2005 | EP1496902A1 Medicaments containing steroids and a novel anticholinesterase drug |
| 01/19/2005 | EP1496900A2 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| 01/19/2005 | EP1496887A1 Personal care compositions comprising a zinc containing material in an aqueous surfactant composition |
| 01/19/2005 | EP1496883A1 Method for treating ileus with an alpha-ketoalkanoic acid, ester or amide |
| 01/19/2005 | EP1496876A2 Aerosol formulation for inhalation comprising a tiotropium salt |
| 01/19/2005 | EP1496875A1 Use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix |
| 01/19/2005 | EP1496873A2 Chewable soft capsule |
| 01/19/2005 | EP1496872A2 Functional foods containing a phospholipid-containing stable matrix |
| 01/19/2005 | EP1496871A1 Polysaccharide capsules and methods of preparation |
| 01/19/2005 | EP1496869A1 Coated particles with prolonged release and tablets containing same |
| 01/19/2005 | EP1496867A1 Drug-complex microparticles and methods of making/using same |
| 01/19/2005 | EP1496863A2 Preparation and use of a stable formulation of allosteric effector compounds |
| 01/19/2005 | EP1496861A2 Method of inhibiting restenosis |
| 01/19/2005 | EP1496859A1 Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate |
| 01/19/2005 | EP1496857A1 Aerosol containing a particulate active substance |
| 01/19/2005 | EP1496851A1 Oral care products containing ovomucin |
| 01/19/2005 | EP1496835A2 Compositions and methods for systemic inhibition of cartilage degradation |
| 01/19/2005 | EP1496751A1 Delivery systems for functional ingredients |
| 01/19/2005 | EP1423019A4 Process for preparing concentrate thickener compositions |
| 01/19/2005 | EP1416963A4 Treating, preventing, or detecting angiogenesis with an anti-a2b antibody |
| 01/19/2005 | EP1392366A4 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 01/19/2005 | EP1362053A4 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 01/19/2005 | EP1361895A4 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 01/19/2005 | EP1355633B1 NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate |
| 01/19/2005 | EP1318721A4 Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions |
| 01/19/2005 | EP1313738A4 Process for the preparation and purification of thiol-containing maytansinoids |
| 01/19/2005 | EP1198494B1 Preparations that are devoid of cross-linking agents |
| 01/19/2005 | EP1165493B1 Nitrogen mustard compounds and prodrugs therefor |
| 01/19/2005 | EP1140038B1 Transdermal drug delivery system |
| 01/19/2005 | EP1121127B1 Oral pharmaceutical compositions containing buprenorphin |
| 01/19/2005 | EP1115478B1 Emollient esters based upon capryl alcohol and isostearic acid |
| 01/19/2005 | EP1087754B1 Method of forming liposomes |
| 01/19/2005 | EP0969807B1 Chitosane microspheres |
| 01/19/2005 | EP0963196B1 Hyaluronic drug delivery system |
| 01/19/2005 | EP0954282B1 Preparation of particles for inhalation |
| 01/19/2005 | EP0642335B2 Controlled release preparation containing a salt of morphine |
| 01/19/2005 | CN1568331A Biological products |
| 01/19/2005 | CN1568197A Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 01/19/2005 | CN1568196A Nutrient therapy for immuno-compromised patients |
| 01/19/2005 | CN1568192A Kahalalide F formulation |
| 01/19/2005 | CN1568181A Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 01/19/2005 | CN1568180A Pharmaceutical formulations for the controlled release of 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1, 2, 3, 4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline |
| 01/19/2005 | CN1568179A Powder processing with pressurized gaseous fluids |
| 01/19/2005 | CN1568178A Injectable composition of paclitaxel |
| 01/19/2005 | CN1568177A Anti-microbial composition comprising a metal ion chelating agent |
| 01/19/2005 | CN1566158A Recombinant vaccine for prevention and treatment of SARS virus |
| 01/19/2005 | CN1565566A Medicine for relieving stagnation by promoting qi circulation and removing pain |
| 01/19/2005 | CN1565523A Percutaneous plaster and its preparation method |
| 01/19/2005 | CN1565487A Gynecopathy treating pills and its preparation method |
| 01/19/2005 | CN1565486A Leucocyte increasing pills and its preparation method |
| 01/19/2005 | CN1565446A Freeze-drying fluconazole injection and its preparation method |
| 01/19/2005 | CN1565445A N-phenylpyrazoles drug containing long-acting injection for animals |
| 01/19/2005 | CN1565444A Ramatroban glue pill and its preparation method |